Mankind Pharma Acquires Rivotril Brand from Roche for India

Mankind Pharma Limited has announced the acquisition of the brand Rivotril from Roche for the Indian market. The agreement grants Mankind Pharma exclusive rights to manufacture, market and distribute the product across the country. 

Rivotril is the innovator brand of clonazepam and is widely prescribed for the treatment of neurological and psychiatric conditions.

The acquisition marks a strategic move for Mankind Pharma as it continues to strengthen its presence in specialty and chronic therapy segments within the pharmaceutical market.

Strengthening the CNS Therapy Portfolio

Rivotril is often regarded as a textbook brand in its category due to its clinical history and recognition among healthcare professionals. The brand is commonly used in the management of neurological conditions and has built strong recall among specialists over the years.

With this acquisition, Mankind Pharma aims to enhance its central nervous system (CNS) therapy portfolio. The addition of Rivotril complements the company’s existing neuro products and strengthens its offerings for the treatment of neurological and psychiatric disorders.

Focus on Expanding Chronic Therapies

Mankind Pharma has been steadily expanding its presence in chronic therapy segments, which include treatments for long-term medical conditions. The company has pursued this strategy through new product launches, partnerships and portfolio acquisitions across various therapeutic areas.

Chronic therapies are becoming an increasingly important part of the company’s business as they provide sustained demand and enable deeper engagement with specialist doctors and healthcare providers.

Leveraging Strong Distribution Network

To support the growth of the Rivotril brand, Mankind Pharma plans to leverage its extensive distribution network and field force. The company currently engages with more than five lakh doctors across the country and has built a strong prescription presence in the Indian pharmaceutical market.

This wide reach allows the company to ensure better access to the medication across hospitals, clinics and healthcare institutions in both urban and semi-urban regions.

Mankind Pharma Share Price Today

On March 18, 2026, Mankind Pharma share price opened at ₹2,066.80. At 11:28 AM, the share price of Mankind Pharma was trading at ₹2,121.10, up by 2.56% on the NSE.

Also Read: Mankind Pharma Share Price Slips 4% Despite Q3 FY26 Earnings Net Profit Growth!

Conclusion

The acquisition of Rivotril reflects Mankind Pharma’s strategic focus on strengthening its presence in specialty and chronic therapy segments. By integrating a well-established brand into its CNS portfolio, the company aims to expand treatment options for patients while further strengthening its position in India’s pharmaceutical market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.